Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Stryker Corporation. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Stryker Corporation (“Stryker” or “the Company”) (NASDAQ: SYK). Investors who purchased Stryker securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Stryker has violated federal securities laws.
Stryker Investigation Details
On July 30, 2026, Stryker reported its second-quarter 2026 results. Among other things, the Company reported that a “supply disruption resulted in a meaningful backorder situation with lost sales in the quarter. We have addressed the issue, and back orders should reach a manageable level by the end of Q3.” Following this news, Stryker’s stock price dropped $22.34 or 6.43% to close at $325.70 per share on July 31, 2026. Then on September 8, 2026, the Company participated in the Wells Fargo Healthcare Conference, during which the Company’s CFO Preston Wells told investors the Company had “anticipated that” the manufacturing issue “would rectify itself in the third quarter.” But “[w]hat we’re seeing is that is continuing into the third quarter and certainly, it will continue.” Following this news, Stryker’s stock price dropped $26.70 per share, or 8.8%, to close at $276.43 per share on September 8, 2026.
What’s Next for Stryker Investors?
If you are aware of any facts relating to this investigation or purchased Stryker securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
SYK — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”